Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 9/2009

01.09.2009 | Review Article

Use of Atomoxetine in Patients with Attention-Deficit Hyperactivity Disorder and Co-Morbid Conditions

verfasst von: Dr Grazia Dell’Agnello, Alessandro Zuddas, Gabriele Masi, Paolo Curatolo, Dante Besana, Andrea Rossi

Erschienen in: CNS Drugs | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Attention-deficit hyperactivity disorder (ADHD) is one of the most common neurobehavioural disorders in children. It has been shown that as many as 85% of patients with ADHD have at least one psychiatric comorbidity, and approximately 60% have at least two.
Atomoxetine is a specific, noradrenergic reuptake inhibitor that provides an effective treatment option for patients with ADHD and co-morbid conditions. The efficacy of atomoxetine in treating ADHD appears to be unaffected by the presence of co-morbid conditions. Therapy with atomoxetine has been associated with statistically significant improvements in symptoms of oppositional defiant disorder in most, but not all, studies. Limited data suggest this agent may have potential in improving co-occurring symptoms of anxiety and may be useful in patients with co-morbid conditions such as tics or Tourette’s syndrome.
The tolerability profile of atomoxetine in patients with ADHD and comorbid conditions was similar to that of patients with uncomplicated ADHD. Atomoxetine was well tolerated, with adverse events generally mild and transient; the most frequent adverse events in patients with ADHD included abdominal pain, decreased appetite, nausea and vomiting.
The favourable safety and efficacy profile of atomoxetine makes it a promising treatment for patients with ADHD and associated co-morbidities.
Literatur
1.
Hechtman L. Assessment and diagnosis of attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 2000 Jul; 9(3): 481–98PubMed
2.
Olfson M. Diagnosing mental disorders in office-based pediatric practice. J Dev Behav Pediatr 1992 Oct; 13(5): 363–5PubMed
3.
Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007 Jun; 164(6): 942–8PubMedCrossRef
4.
Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006 Feb; 36(2): 159–65PubMedCrossRef
5.
Biederman J, Monuteaux MC, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med 2006 Feb; 36(2): 167–79PubMedCrossRef
6.
7.
Kadesjö B, Gillberg C. The comorbidity of ADHD in the general population of Swedish school-age children. J Child Psychol Psychiatry 2001; 42: 487–92PubMedCrossRef
8.
MTA Cooperative Group. A 14-month randomised clinical trial of treatment strategies for attention-deficit/ hyperactivity disorder: the MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999 Dec; 56(12): 1073–86CrossRef
9.
Steinhausen H, Metzke C, Meier M, et al. Prevalence of child and adolescent psychiatric disorders: the Zurich Epidemiological Study. Acta Psychiatr Scand 1998; 98: 262–71PubMedCrossRef
10.
Steinhausen H-C, Novik T, Baldursson G, et al. Coexisting psychiatric problems in ADHD in the ADORE cohort. Eur Child Adolesc Psychiatry 2006; 15 Suppl. 1: 25–9CrossRef
11.
Dunn DW, Austin JK, Caffrey HM, et al. A prospective study of teachers’ ratings of behaviour problems in children with new-onset seizures. Epilepsy Behav 2003 Feb; 4(1): 26–35PubMedCrossRef
12.
13.
Lewinsohn PM, Rohde P, Seeley JR. Adolescent psychopathology III: the clinical consequences of comorbidity. J Am Acad Child Adolesc Psychiatry 1995; 34: 510–9PubMedCrossRef
14.
Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001; 40: 147–58PubMedCrossRef
15.
March JS, Swanson JM, Arnold LE, et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). J Abnorm Child Psychol 2000 Dec; 28(6): 527–41PubMedCrossRef
16.
Consoli A, Bouzamondo A, Guilé JM, et al. Comorbidity with ADHD decreases response to pharmacotherapy in children and adolescents with acute mania: evidence from a metaanalysis. Can J Psychiatry 2007 May; 52(5): 323–8PubMed
17.
Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 2008; 22(3): 213–37PubMedCrossRef
18.
Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/ hyperactivity disorder, including an assessment of evening and morning behaviour: a double-blind, placebo-controlled trial. Pediatrics 2004 Jul; 114(1): e1–8PubMedCrossRef
19.
Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomised prospective study. Adv Ther 2005 Sep–Oct; 22(5): 498–512PubMedCrossRef
20.
Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomised, open-label trial. J Am Acad Child Adolesc Psychiatry 2002 Jul; 41(7): 776–84PubMedCrossRef
21.
Michelson D. A double-blind placebo-controlled comparison of atomoxetine, OROS methyphenidate and placebo. American Academy of Child and Adolescent Psychiatry Meeting; 2004 Oct 19–23; Washington, DC
22.
Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomised, placebo-controlled studies. Biol Psychiatry 2003 Jan 15; 53(2): 112–20PubMedCrossRef
23.
Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomised, placebo-controlled study. Am J Psychiatry 2002 Nov; 159(11): 1896–901PubMedCrossRef
24.
Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomised, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004 Jul; 43(7): 896–904PubMedCrossRef
25.
Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomised, placebo-controlled, dose-response study. Pediatrics 2001 Nov; 108(5): E83PubMedCrossRef
26.
Michelson D, Gao H, Allen AJ, et al. Plasma atomoxetine concentration and response to ADHD in children and adolescents. 42nd Annual Meeting of the New Clinical Drug Evaluation Unit; 2002 Jun 10–13; Boca Raton (FL)
27.
Sangal R, Owens J, Allen AJ, et al. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep 2006; 29: 1573–85PubMed
28.
Spencer T, Biederman J, Heiligenstein J, et al. An openlabel, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001 Fall; 11(3): 251–65PubMedCrossRef
29.
Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998 May; 155(5): 693–5PubMed
30.
Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002 Dec; 63(12): 1140–7PubMedCrossRef
31.
Weiss M, Tannock R, Kratochvil C, et al. A randomised, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005 Jul; 44(7): 647–55PubMedCrossRef
32.
Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005 Aug; 9(1): 275–89PubMedCrossRef
33.
Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008 Jun; 165(6): 721–30PubMedCrossRef
34.
DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD rating scale-IV: checklists, norms, and clinical interpretation. New York: The Guildford Press, 1998
35.
Connors CK. Connors’ rating scales: revised technical manual. North Tonawanda (NY): Multi-Health Systems, Inc., 1997
36.
Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006 Aug; 45(8): 919–27PubMedCrossRef
37.
Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/ hyperactivity disorder. J Pediatr 2006 Jul; 149(1): 112–9PubMedCrossRef
38.
Turgay A. Atomoxetine in the treatment of children, adolescents and adults with attention deficit hyperactivity disorder. Future Drugs 2006; 3: 19–38
39.
Wolraich M, Wibbelsman C, Brown T, et al. Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics 2005; 115: 1734–46PubMedCrossRef
40.
Kaplan S, Heiligenstein J, West S, et al. Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord 2004; 8: 45–52PubMedCrossRef
41.
Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. Pediatrics 2008; 121(2): 314–20CrossRef
42.
Bangs ME, Hazell P, Danckaerts M, et al. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20–25; Toronto (ON)
43.
Newcorn JH, Spencer TJ, Biederman J, et al. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 240–8PubMedCrossRef
44.
Kratochvil CS, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 2005; 44: 915–24PubMedCrossRef
45.
Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/ hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 1119–27PubMedCrossRef
46.
Sumner C, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with ADHD and comorbid anxiety [abstract]. Int J Neuropsychopharmacol 2006; 9 Suppl. 1: 135
47.
Atomoxetine ADHD and Comorbid MDD Study Group, Bangs ME, Emslie GJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/ hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 2007 Aug; 17(4): 407–20PubMedCrossRef
48.
Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005 Dec; 65: 1941–9PubMedCrossRef
49.
Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006 Oct; 45: 1196–205PubMedCrossRef
50.
August GJ, Realmuto GM, MacDonald 3rd AW, et al. Prevalence of ADHD and comorbid disorders among elementary school children screened for disruptive behaviour. J Abnorm Child Psychol 1996 Oct; 24(5): 571–95PubMedCrossRef
51.
Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991 May; 148(5): 564–77PubMed
52.
Goldman LS, Genel M, Bezman RJ, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998 Apr; 279(14): 1100–7CrossRef
53.
Greene RW, Biederman J, Zerwas S, et al. Psychiatric comorbidity, family dysfunction, and social impairment in referred youth with oppositional defiant disorder. Am J Psychiatry 2002 Jul; 159(7): 1214–24PubMedCrossRef
54.
Kuhne M, Schachar R, Tannock R. Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997 Dec; 36(12): 1715–25PubMedCrossRef
55.
Biederman J, Spencer T, Newcorn J, et al. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. Psychopharmacology (Berl) 2007; 190: 31–41CrossRef
56.
Dunne JE. Attention-deficit/hyperactivity disorder and associated childhood disorders. Prim Care 1999 Jun; 26(2): 349–72PubMedCrossRef
57.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
58.
Curatolo P, Mancini F, Dell’Agnello G, The LYCY Study Group. Quality of life of pediatric patients with attention-deficit/hyperactivity disorder and oppositive defiant disorder: an Italian double-blind, placebo-controlled study with atomoxetine. The 13th International Congress of the European Society for Child and Adolescent Psychiatry; 2007 Aug 25–29; Florence
59.
Hazell P, Zhang S, Wolañczyk T, et al. Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/ hyperactivity disorder. Eur Child Adolesc Psychiatry 2006; 15: 105–10PubMedCrossRef
60.
Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001; 40(2): 168–79PubMedCrossRef
61.
Pliszka SR. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. J Clin Psychiatry 1998; 59 Suppl. 7: 50–8
62.
Kunwar A, Dewan M, Faraone SV. Treating common psychiatric disorders associated with attention-deficit/ hyperactivity disorder. Expert Opin Pharmacother 2007 Apr; 8(5): 555–62PubMedCrossRef
63.
Heiligenstein J, Spencer T, Faries DE, et al. Efficacy of atomoxetine vs placebo in pediatric outpatients with ADHD. Proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington, DC: AACAP, 2000
64.
Poznanski EO, Mokros HB. Children’s Depression Rating Scale (CDRS-R) revised. Los Angeles (CA): Western Psychological Services, 1999
65.
Keen D. ADHD and the paediatrician: a guide to management. Curr Paediatr 2005; 15: 133–42CrossRef
66.
Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville (MD): U.S. Department of Health, Education, and Welfare, 1976. Publication ADM 76-338
67.
Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989 Jul; 28(4): 566–73PubMedCrossRef
68.
Cohen DJ, Leckman JF, Shaywitz BA. The Tourette’s syndrome and other tics. In: Shaffer D, Erhardt AA, Greenhill L, editors. Diagnosis and treatment in pediatric psychiatry. New York: MacMillan Free Press, 1984
69.
Spencer TJ, Sallee FR, Gilbert DL, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord 2008 Jan; 11(4): 470–81PubMedCrossRef
70.
Sturm H, Fernell E, Gillberg C. Autism spectrum disorders in children with normal intellectual levels: associated impairments and subgroups. Dev Med Child Neurol 2004 Jul; 46(7): 444–7PubMedCrossRef
71.
Aman MG, Singh NN, Stewart AW, et al. The Aberrant Behavior Checklist: a behaviour rating scale for the assessment of treatment effects. Am J Ment Defic 1985 Mar; 89(5): 485–91PubMed
72.
Troost P, Steinhuis M-P, Tuynman-Qua H, et al. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol 2006 Oct; 16: 611–9PubMedCrossRef
73.
Posey DJ, Wiegand RE, Wilkerson J, et al. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006 Oct; 16(5): 599–610PubMedCrossRef
74.
Jou RJ, Handen BL, Hardan AY. Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2005 Apr; 15(2): 325–30PubMedCrossRef
75.
Faraone SV, Biederman J, Wozniak J, et al. Is comorbidity with ADHD a marker for juvenile-onset mania? J Am Acad Child Adolesc Psychiatry 1997 Aug; 36(8): 1046–55PubMedCrossRef
76.
Findling RL, Gracious BL, McNamara NK, et al. Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. Bipolar Disord 2001 Aug; 3(4): 202–10PubMedCrossRef
77.
Kafantaris V, Coletti DJ, Dicker R, et al. Are childhood psychiatric histories of bipolar adolescents associated with family history, psychosis, and response to lithium treatment? J Affect Disord 1998 Nov; 51(2): 153–64PubMedCrossRef
78.
Kutcher S, Robertson HA, Bird D. Premorbid functioning in adolescent onset bipolar I disorder: a preliminary report from an ongoing study. J Affect Disord 1998 Nov; 51(2): 137–44PubMedCrossRef
79.
Masi G, Perugi G, Toni C, et al. Attention-deficit hyperactivity disorder: bipolar comorbidity in children and adolescents. Bipolar Disord 2006 Aug; 8(4): 373–81PubMedCrossRef
80.
West SA, McElroy SL, Strakowski SM, et al. Attention deficit hyperactivity disorder in adolescent mania. Am J Psychiatry 1995 Feb; 152(2): 271–3PubMed
81.
Geller B, Zimerman B, Williams M, et al. DSM-IV mania symptoms in a prepubertal and early adolescent bipolar disorder phenotype compared to attention-deficit hyperactive and normal controls. J Child Adolesc Psychopharmacol 2002 Spring; 12(1): 11–25PubMedCrossRef
82.
Jaworowski S, Benarroch F, Gross-Tsur V. Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/ hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome. J Child Adolesc Psychopharmacol 2006; 16: 365–70PubMedCrossRef
83.
Hah M, Chang K. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol 2005; 15: 996–1004PubMedCrossRef
84.
Pliszka SR, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. Am Acad Child Adolesc Psychiatry 2007 Jul; 46(7): 894–921CrossRef
85.
86.
King S, Griffin S, Hodges Z, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess 2006 Jul; 10(23): iii–iv, xiii-146PubMed
87.
Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26(10): 729–40PubMedCrossRef
88.
Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002; 63 Suppl. 12: 50–5
89.
90.
Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008; 31(4): 345–54PubMedCrossRef
91.
Lim JR, Faught PR, Chalasani NP, et al. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr 2006 Jun; 148(6): 831–4PubMedCrossRef
92.
Stojanovski SD, Casavant MJ, Mousa HM, et al. Atomoxetine-induced hepatitis in a child. Clin Toxicol (Phila) 2007; 45(1): 51–5CrossRef
93.
Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behaviour events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008 Feb; 47(2): 209–18PubMedCrossRef
94.
Lee TS, Lee TD, Lombroso PJ, et al. Atomoxetine and tics in ADHD. J Am Acad Child Adolesc Psychiatry 2004 Sep; 43(9): 1068–9PubMedCrossRef
95.
Párraga HC, Párraga KL, Harris DK, et al. Abdominal tics during atomoxetine treatment in a child with ADHD: evaluation and differential diagnosis [letter]. CNS Spectr 2008 Sep; 13(9): E1PubMed
96.
Párraga HC, Párraga MI, Harris DK. Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder. Int J Psychiatry Med 2007; 37(4): 415–24PubMedCrossRef
97.
Sawant S, Daviss SR. Seizures and prolonged QTc with atomoxetine overdose [letter]. Am J Psychiatry 2004 Apr; 161(4): 757PubMedCrossRef
98.
Spiller HA, Lintner CP, Winter ML. Atomoxetine ingestions in children: a report from poison centers. Ann Pharmacother 2005 Jun; 39(6): 1045–8PubMedCrossRef
99.
Wernicke JF, Holdridge KC, Jin L, et al. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Dev Med Child Neurol 2007 Jul; 49(7): 498–502PubMedCrossRef
100.
Wernicke JF, Chilcott K, McAfee A, et al. Seizure risk in patients with ADHD treated with atomoxetine. Annual Meeting of the American Academy of Children and Adolescent Psychiatry; 2005 Oct 18–23; Toronto (ON)
101.
Dunn DW, Austin JK, Harezlak J, et al. ADHD and epilepsy in childhood. Dev Med Child Neurol 2003 Jan; 45(1): 50–4PubMedCrossRef
102.
Hesdorffer DC, Ludvigsson P, Olafsson E, et al. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Arch Gen Psychiatry 2004 Jul; 61(7): 731–6PubMedCrossRef
103.
Double blind, placebo controlled, crossover study of extended release methylphenidate for treatment of ADHD in children with epilepsy [ClinicalTrials.gov identifier NCT00323947]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: http://​www.​clinicaltrials.​gov [Accessed 2009 Jan 30]
104.
Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child 2005 Feb; 90Suppl. 1: i26–9PubMedCrossRef
105.
Olfson M. New options in the pharmacological management of attention-deficit/hyperactivity disorder. Am J Manag Care 2004 Jul; 10(4 Suppl.): S117–24PubMed
106.
Prasad S, Steer C. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder: clinical approaches and review of current available evidence. Pediatr Drugs 2008; 10(1): 39–47CrossRef
107.
National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. Clinical guideline 72 [online]. Available from URL: http://​www.​nice.​org.​uk/​CG72 [Accessed 2008 Dec 17]
Metadaten
Titel
Use of Atomoxetine in Patients with Attention-Deficit Hyperactivity Disorder and Co-Morbid Conditions
verfasst von
Dr Grazia Dell’Agnello
Alessandro Zuddas
Gabriele Masi
Paolo Curatolo
Dante Besana
Andrea Rossi
Publikationsdatum
01.09.2009
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 9/2009
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/11314350-000000000-00000

Weitere Artikel der Ausgabe 9/2009

CNS Drugs 9/2009 Zur Ausgabe

Adis Drug Profile

Armodafinil

Leading Article

Tumour Necrosis Factor Modulation for Treatment of Alzheimer’s Disease

Review Article

Neuropeptide and Sigma Receptors as Novel Therapeutic Targets for the Pharmacotherapy of Depression

Review Article

The Effect of Migraine Prophylaxis on Migraine-Related Resource Use and Productivity

Review Article

Aripiprazole

Adis Drug Profile

Asenapine

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise